UK Study Provides New Insight on Colorectal Cancer Growth
LEXINGTON, Ky. (July 14, 2020) — A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase (SMS) to facilitate colorectal cancer growth.
SMS is an enzyme that produces spermine from spermidine, which has been shown to be important for cell growth. However, excessive accumulation of spermidine can have harmful effects on cell viability. How cancer cells maintain a relatively high level of spermidine but below the toxic threshold to facilitate tumor growth is not well understood.
A group led by the Markey Cancer Center researcher Qing-Bai She, a professor in the UK College of Medicine’s Department of Pharmacology and Nutritional Sciences, discovered that SMS is overexpressed in colorectal cancers and plays an important role in balancing cellular spermidine levels that are a necessary adaptation for colorectal cancer growth.
The group further revealed a link between the signaling of SMS and the oncogene MYC, a gene that plays a role in many cancer types, to maintain colorectal cancer cell survival. The study showed that combined inhibition of SMS and MYC signaling induced cancer cell death and tumor regression, which could be a promising strategy for colorectal cancer therapy.
“Our findings provide an in-depth understanding of how the polyamine metabolic pathway interacts with oncogenic signaling pathways in tumorigenesis and highlight the unmet need of clinically effective SMS inhibitors for the targeted therapy,” said She.
The findings were published on June 26, 2020 in Nature Communications.
This work was supported, in part, by funding from the National Cancer Institute, the National Institute of General Medical Sciences, the UK Markey Cancer Center, and the UK Center for Clinical and Translational Sciences. Researchers from the Southern Medical University and the Greenwood Genetic Center collaborated with UK scientists in this study.
As the state’s flagship, land-grant institution, the University of Kentucky exists to advance the Commonwealth. We do that by preparing the next generation of leaders — placing students at the heart of everything we do — and transforming the lives of Kentuckians through education, research and creative work, service and health care. We pride ourselves on being a catalyst for breakthroughs and a force for healing, a place where ingenuity unfolds. It's all made possible by our people — visionaries, disruptors and pioneers — who make up 200 academic programs, a $501 million research and development enterprise and a world-class medical center, all on one campus.
In 2022, UK was ranked by Forbes as one of the “Best Employers for New Grads” and named a “Diversity Champion” by INSIGHT into Diversity, a testament to our commitment to advance Kentucky and create a community of belonging for everyone. While our mission looks different in many ways than it did in 1865, the vision of service to our Commonwealth and the world remains the same. We are the University for Kentucky.